Subcutaneous Daratumumab Potential Game Changer For Multiple Myeloma - Peter M. Goodwin

Subcutaneous administration of the anti-CD38 monoclonal antibody daratumumab could make it possible for more patients to receive this emerging therapy more easily for their advanced or recently diagnosed multiple myeloma, according to research reported at the 2017 American Society of Hematology Annual Meeting. “It's one of those rare things in medicine where you have a drug that seems to be safer, with lower rates of infusion reaction, seems to be more convenient, and seems to have comparable efficacy,” said study author Ajai Chari, MD, associate professor of medicine, hematology, medical oncology, director of clinical research in the multiple myeloma program and associate director of clinical research at the Mount Sinai Cancer Clinical Trials Office at the Icahn School of Medicine at Mount Sinai. “So I think those things speak for themselves. These are really exciting results and I think it speaks to the reason why there are four phase III studies going on using this formulation.”

• Ajai Chari, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Icahn School of Medicine at Mount Sinai
  Learn more